Trials / Terminated
TerminatedNCT02536300
Dose Optimization Study of Idelalisib in Follicular Lymphoma
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idelalisib | Idelalisib tablet administered orally |
Timeline
- Start date
- 2016-01-14
- Primary completion
- 2022-09-27
- Completion
- 2022-09-27
- First posted
- 2015-08-31
- Last updated
- 2023-08-14
- Results posted
- 2023-08-14
Locations
66 sites across 10 countries: Australia, Canada, Czechia, France, Israel, Italy, Poland, Romania, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02536300. Inclusion in this directory is not an endorsement.